Solventum Co. (NYSE:SOLV) Given Average Rating of “Hold” by Analysts

Shares of Solventum Co. (NYSE:SOLV) have earned a consensus rating of “Hold” from the eleven analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $68.29.

SOLV has been the subject of a number of recent analyst reports. Wolfe Research started coverage on shares of Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating for the company. Morgan Stanley boosted their target price on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Piper Sandler increased their price target on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Mizuho assumed coverage on Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective for the company. Finally, Stifel Nicolaus initiated coverage on Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock.

Solventum Stock Performance

Shares of NYSE SOLV opened at $66.83 on Monday. The business has a 50 day moving average price of $70.90 and a two-hundred day moving average price of $63.55. Solventum has a fifty-two week low of $47.16 and a fifty-two week high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Institutional Investors Weigh In On Solventum

Several large investors have recently added to or reduced their stakes in the stock. Davis Selected Advisers bought a new position in shares of Solventum during the second quarter worth about $273,070,000. Nuance Investments LLC bought a new stake in shares of Solventum during the second quarter valued at approximately $115,829,000. Newport Trust Company LLC acquired a new position in shares of Solventum during the second quarter worth approximately $98,976,000. Baupost Group LLC MA bought a new position in Solventum in the 2nd quarter worth approximately $96,242,000. Finally, Hotchkis & Wiley Capital Management LLC acquired a new stake in Solventum in the 3rd quarter valued at approximately $125,488,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.